Amryt Pharma PLC Distribution Agreement Signed Covering Switzerland (1618B)
08 January 2018 - 6:00PM
UK Regulatory
TIDMAMYT
RNS Number : 1618B
Amryt Pharma PLC
08 January 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Distribution Agreement Signed in Switzerland
Amryt, a biopharmaceutical company focused on rare and orphan
diseases, is pleased to announce that it has signed an exclusive
distributor agreement for Lojuxta(R) (lomitapide) in Switzerland.
The agreement is with RCC Pharma AG ("RCC"), a leading Swiss
pharmaceutical company with expertise in early access programs in
rare and orphan diseases.
Lojuxta is a treatment for Homozygous Familial
Hypercholesterolemia ("HoFH"), a rare, life-limiting disease, which
impairs the body's ability to remove LDL cholesterol ("bad"
cholesterol) from the blood. Starting before birth, the disease
progresses rapidly, and typically results in extremely high blood
LDL cholesterol levels, which leads to aggressive and premature
narrowing and blocking of blood vessels. Left untreated, heart
attack or sudden death may occur in childhood or early
adulthood.
The Company currently estimates that there are approximately 15
patients with HoFH in Switzerland. It has received requests from
clinicians for access to Lojuxta for Swiss patients and this
agreement will now enable Amryt to respond more effectively to such
requests. The new agreement follows a distribution agreement,
announced on 13 November, which covers Amryt's products for the
Kingdom of Saudi Arabia.
Amryt acquired exclusive marketing rights for Lojuxta in the
European Economic Area, Switzerland, Middle East, North Africa,
Turkey and Israel in December 2016.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma,
said:
"This new distribution agreement with RCC marks another key step
as we expand our footprint for Lojuxta across Europe, the Middle
East, and North Africa. RCC is a leading Swiss company with
particular expertise in rare diseases, and this agreement will help
us to bring Lojuxta to patients suffering from HoFH in
Switzerland.
"We continue to work on further partnerships across our licensed
territories for Lojuxta, and look forward to announcing further
developments."
Enquiries:
C/o KTZ Communications
Amryt Pharma plc (details below)
Joe Wiley, CEO
Rory Nealon, CFO/COO
Shore Capital +44 (0) 20 7408 4090
Nomad and Joint Broker
Edward Mansfield, Mark
Percy
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene
Bermont-Penn, Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty biopharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the European Economic Area, Middle
East and North Africa, Turkey and Israel. Lojuxta is used to treat
a rare life-threatening disease called Homozygous Familial
Hypercholesterolemia, which impairs the body's ability to remove
LDL cholesterol ("bad" cholesterol) from the blood. This typically
results in extremely high blood LDL cholesterol levels, leading to
aggressive and premature narrowing and blocking of arterial blood
vessels. If left untreated, heart attack or sudden death may occur
in childhood or early adulthood.
Amryt's lead drug candidate, AP101, is a potential treatment for
Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children for which there is currently no
treatment. It is currently in Phase 3 clinical trials. The global
market opportunity for EB is estimated to be in excess of EUR 1.3
billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
About RCC Pharma AG
(www.rcc-pharma.com)
RCC Pharma is a global pharmaceutical company providing services
to improve the lives of patients. Headquartered in Switzerland
since 1993, RCC Pharma focuses on early access programs and product
development to a global network of doctors, hospitals and
Government organizations.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRBSGDBLUGBGIL
(END) Dow Jones Newswires
January 08, 2018 02:00 ET (07:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024